Growing knowledge of the diseases in the nervous system combined with new gains in gene technology make the timing right for a dedicated and focused effort to develop new cell and gene based products for the treatment of neurological diseases. Biologics open a wide range of new ways to treat diseases and offer realistic hopes for the development of treatments of today incurable diseases. NsGene is with its unique proprietary factors and EC BiodeliveryTM platform an attractive and interesting partner for biotechnology or pharmaceutical companies developing therapies for the treatment of neurological diseases.
NsGene presents a number of interesting partnering opportunities within its R&D programs. NsGene seeks collaboration partners to develop, market, and sell EC BiodeliveryTM products for Alzheimer’s disease (NsG0202) and epilepsy (NsG0501). In addition, NsGene seeks partners to develop EC BiodeliveryTM products as a delivery technology platform for other neurological diseases. With regard to factor products, NsGene seeks co-development partners to commercialise CNS applications of Neublastin, NsG33 (Meteorin), and all the proprietary pipeline factors.
Please contact:
Vice President Business Development, Bent U. Frandsen
Tel: +45 4460 8911
Email: buf(a)nsgene.dk
NsGene is an attractive partner as:
NsGene has developed a superior biodelivery device to deliver biologics across the blood brain barrier
NsGene develops unique biological products for major diseases in the nervous system
NsGene has an impressive track record of finding promising new biologics
NsGene has built strong academic and corporate networks
NsGene's business strategy has been effectively executed in partnerships with Biogen Idec, Neurotech, and Stem Cell Sciences
